Dr. Jay Tong
President & CEO
Jay Tong, M.D, founded AllCells, LLC in 1998 and has served as the company’s President & CEO since that time. While working as a Research Scientist at Novartis-Systemix (Palo Alto, CA) in the 1990s, Dr. Tong recognized an industry need for a readily available commercial source of hematologic tissue such as bone marrow, cord & peripheral blood, and purified hematology & immunology primary cell types needed to support scientific research, drug discovery and development. Jay Tong earned his M.D. from Suzhou Medical College in China, and completed graduate studies in Hematology at Henan University at Zheng Zhou. He later completed his Hematology Fellowship at the prestigious Genoa Medical School in Italy, a world leader in bone marrow transplantation. Additional post-doctoral training took Dr. Tong to Dr. Ronald Hoffman’s Lab at Indiana University Medical School at Indianapolis. Dr. Tong has published over thirty (30) peer reviewed papers relating to stem cell purification, ex vivo expansion, gene transduction, and hematopoietic stem cell transplantation.
Vice President of Corporate Development
Wayne Vaz, Vice President Corporate Development, joined AllCells, LLC in 2010 as a member of the company’s executive leadership team responsible for commercial strategy and helping transform the company into a market leader.
Mr. Vaz has held executive positions in Canada and U.S covering areas of corporate business development, technology & alliance, technology roadmapping, strategic planning, M&A, market channel development, technical services, and quality assurance. Prior to joining AllCells Wayne served with leading Life Science companies including Millipore (NYSE: MIL), Serologicals Corp. (NASDAQ: SERO), Celliance (a Serologicals Company), Intergen Company, and Canada Packers Biochemicals Division, with emphasis on commercializing cell-based products, reagents, and gene expression technologies used in biopharmaceutical production, drug discovery & development, and cell/tissue therapy. Wayne received his Honors Biochemistry B.Sc. from University of Toronto, Canada.
Lewis P. Chapman
Vice President, Global Commercial Operations
Lewis Chapman joined AllCells’ executive team January 11, 2016. Mr. Chapman is a seasoned Commercial Executive with over 30 years of experience in Marketing, Sales and Business Development at both small and large Life Science, Biopharmaceutical, and Medical Device companies. Mr. Chapman’s most recent corporate position was with BioMarin Pharmaceutical, Inc. where he served for over five years as Vice President, Global & Strategic Marketing. There he was responsible for a range of international commercial functions including product management, new product introductions, global market research, forecasting, new product planning, business intelligence and alliance management.
Lewis’ stem cell and cell therapy business experience includes Xcyte Therapies, Inc (Chief Business Officer, Vice President of Strategic Marketing & Business Development), Nexell Therapeutics, Inc. (Vice President, Global Marketing), and Triton Biosciences/Berlex Laboratories (Executive Director of Marketing & Sales). He has worked extensively in oncology/hematology, infectious diseases and immunology. His relevant Life Science/Diagnostic company experience includes Alpha Innotech Corp. (Vice President, Global Marketing & Sales), and LifeScan (Group Product Manager).
Lewis holds a BS, Biological Sciences from University of California, Davis, and an MBA from Southern Illinois University.
Rob Frankenberg PhD, PMP, CPIM, CSCP
Vice President of Manufacturing Operations
Rob Frankenberg joined AllCells’ executive team June 20, 2016. Rob brings to AllCells 24+ years global experience in (1) processing of recombinant biologics, chemicals and diagnostic reagents; (2) optimizing operations, while meeting safety, cGMP and ISO regulations; (3) resolution of complex discrepancies to regulatory expectations through root cause analysis and continuous improvement; (4) providing technical stewardship of operations through management of technology and statistical process control; (5) co-inventing of commercial purification processes; (6) effectiveness in influence management of multiple global contract manufacturing and contract research organizations.
Previously Rob was GMP Operations Manager at Bio-Rad Laboratories, accountable for the operational leadership of Bio-Rad’s GMP clinical diagnostics consumables manufacturing operation representing >$250M in annual sales and a production team of 29 team members and 3 supervisors. He was responsible for operations management within SAP, optimization of resource utilization, project management of continuous improvement, facility startup and expansion initiatives and capital projects. Rob holds Bachelor of Science in Biochemistry (UC Davis), a Ph.D. in Bioengineering (UCSF and UC Berkeley) with a Certificate in Management of Technology (Haas School Of Business), a Project Management Professional (PMP, PMI) Certification, a certification in Production and Inventory Management (CPIM, APICS) and a certification as a Supply Chain Professional (CSCP, APICS).
Timothy C. Fong, PhD, MBA
Vice President, Science & Technology
Tim Fong joined the executive team March 16, 2017. Tim has over 20 years of biotech industry experience with broad expertise in therapeutic drug discovery and development. Tim has led teams in discovery research, preclinical studies, product characterization, and GMP manufacturing process development in several platform technologies, including cell and gene therapy, bio-active peptides and recombinant protein with a focus on cancer immunotherapy, angiogenesis, autoimmunity, and inflammatory diseases. He has held positions of increasing responsibility at Chiron (Novartis), Aventis Gencell, Sangstat (Genzyme), BD Biosciences, Progenitor Cell Therapy (NeoStem), and Cellerant.
Tim earned his doctorate in Immunology from the Department of Microbiology & Immunology, UCLA School of Medicine, and completed postdoctoral fellowships at the Salk Institute in La Jolla, CA, and at UC San Diego. Tim also hold an MBA from St. Mary’s College, CA. He is a past member of the Product and Process Development and Immunotherapy Committees, International Society for Cell Therapy, and a member of the American Association of Cancer Research, American Society for Hematology, American Association of Immunologists, and Society for Immunotherapy of Cancer.
Ted Parenti, Director of Finance, joined AllCells LLC in May 2016. Mr. Parenti brings to AllCells extensive experience in cost accounting, capital investment and budget, and forecast/analysis using ERP systems. Ted has primary responsibility for leading the company’s accounting control, financial reporting, and forecasting processes.
Prior to joining AllCells Mr. Parenti served as Industrial Controller with Bio-Rad Laboratories, Inc. where he was responsible for financial control covering multiple operational sites within Bio-Rad’s life science division. Ted has held several financial management positions including Cost Accounting Manager at Peet’s Coffee & Tea, Cost Manager with The Clorox Company, Regional Finance Manager with General Mills Operations, Inc., and others.
Director, Enterprise Systems & IT
Don is a seasoned technology leader with a long track record of successfully leveraging technology to enable business success and has been a part of the AllCell’s team since early 2016. Don is highly experienced in technology solutions such as: ERP, CRM, E-commerce, Finance, Retail, Marketing and Supply Chain – across multiple vertical industries. He has been especially instrumental in working with AllCells to re-architect their IT infrastructure, resulting in employees having better and more reliable tools which facilitate teamwork and collaboration. Most exciting is the leadership he has provided in implementation of a completely new enterprise software platform that will greatly enhance AllCell’s capabilities to deliver product, manage the business and serve our customers. He has a strong track record of delivering cost effective and highly available infrastructure and specializes in fixing technologies that are ineffective, broken and costly. Don has led teams from angel startups to large fortune 500 sized companies.